Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EMA Says Yes To GSK’s Omjjara, UCB’s Rystiggo and Novartis’ Spexotras

10 Nov 2023

• By Eliza Slawther

3d render of Europe map Earth globe — Eight drugs are nearing the EU market

Related Content

Success For Mirati As EMA Backs Krazati For EU Approval After Initial Rejection

13 Nov 2023

EU Decision Time For GSK’s Rare Cancer Drug Momelotinib & Others

06 Nov 2023

Mirati To Challenge EMA’s Rejection Of US-Approved Krazati

21 Jul 2023

GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey

18 Sep 2023

Alvotech And Stada Scoop First EU Stelara Biosimilar

10 Nov 2023

Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal

09 Apr 2022

UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG

28 Jun 2023

Related Companies

GSK plc

UCB S.A.

Novartis AG

Mirati Therapeutics, Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Additional Topics

Europe EU Regulation Rare Diseases Review Pathway Market Access Drug Review Biosimilars Approvals BioPharmaceutical Cancer Blood & Coagulation Disorders Immune Disorders Ophthalmic

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.